HCC Prevention and Diagnosis Mapping Survey
DiCE’s ongoing research project aimed at mapping the status quo in the prevention and diagnosis of hepatocellular carcinoma (HCC) across the ...
DiCE is a Partner in HoloSurge: a Horizon Grant-Winning Project on Holographic Surgical Planning
DiCE is a partner in the HoloSurge project, which was awarded a Horizon Europe grant to improve surgical planning with hologram technology. One of ...
Extending the Liver Cancer Index: HCC Prevention and Diagnosis Mapping
DiCE is launching its research project to map the status quo in preventing and treating hepatocellular carcinoma (HCC) across the EU. We will creat...
COR2ED’s New Resources on Advanced HCC
COR2ED is an independent medical education company that develops impactful educational programmes within specific therapeutic areas. They have rece...
ASCO GI Highlights – Positive Data in Earlier Stage HCC Results
The American Society for Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) was held in San Francisco, USA 18-20 January this year. At ...
EU Commission Approval of Tibsovo® (Ivosidenib) in IDH1-mutated Cholangiocarcinoma
The European Commission approved the use of Tibsovo® (Ivosidenib) as monotherapy for the treatment of locally advanced or metastatic cholangiocarc...
Collaboration with COR2ED – HCC CONNECT
DiCE is pleased to collaborate with HCC CONNECT. HCC CONNECT is an international group of experts in hepatocellular carcinoma (HCC).
...
Liver Cancer Index – Data Gaps
DiCE has started disseminating a survey this spring among clinicians, public health experts, and patient advocates to help to sketch the landscape ...
Highlights from the EASL Liver Cancer Summit
The European Association for the Study of the Liver (EASL) held the Liver Cancer Summit, its annual conference focused on liver cancer in Estoril, ...
